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Investigating the role of Abro1 in DNA damage-induced immune response
Ahmed Emam, BS
Advisory Professor: Bin Wang, Ph.D.

Abstract
Genomic instability can be induced by various forms of genotoxic stress and it is
a hallmark of human cancer that is associated with metastasis, therapeutic resistance,
and poor prognosis. During replication stress, the replication fork stalls and forms a
reversed fork which may be degraded by several DNA nucleases. At the stalled fork,
genome stability is maintained by fork end protection and subsequent restart of the
replication. Abro1 has been shown to play an important role in protecting the integrity of
the stalled replication forks by inhibiting DNA2 nuclease. Deficiency of Abro1 leads to
stalled replication fork degradation and genomic instability. Moreover, Abro1-null mice
show signs of inflammatory response such as enlarged spleens, increased numbers of
T cells and B cells, elevated levels of IL6 and TNF-alpha in the blood, and increased
immune cell infiltration in major organs. Recently, it has been shown that genomic
instability can trigger cGAS/STING pathway , inducing activation of the innate immune
response and inflammatory gene expression through cGAS binding to cytoplasmic DNA
or localizing to micronuclei in response to DNA damage. Here, I found that replication
stress induced by Abro1 deficiency leads to ssDNA accumulation in the cytoplasm
triggering activation of the cGAS/STING pathway with upregulation of inflammatory
genes and increase of the secretion of chemokines, which direct the migration of immune
cells. My results suggest possibilities to modulate the host immune system response and
ultimately the success of immune checkpoint blockade therapies.
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Chapter 1: Introduction
1.1

Genomic instability and cancer
With every cell division, the genome must be fully replicated correctly to ensure

genomic stability [1]. Genome stability is a characteristic that allows every organism to
preserve and correctly pass their genetic material between generations or during
cellular division. This includes an error-free replication of genetic material and repair of
replication mistakes or damaged genetic material. Genome stability is critical for cell
survival and normal cell growth. Though necessary for evolution and genetic diversity,
genomic instability is usually linked with pathological disorders. Genomic instability
happens in the form of mutations and chromosomal rearrangements. In humans,
genomic instability is often connected with premature ageing, cancer predisposition and
inherited diseases [2]. Genomic instability is one of the hallmarks of human cancer, and
it is associated with poor prognosis, metastasis, and therapeutic resistance. Genomic
instability can be induced by different types of genotoxic stress, ranging from replication
stress, failure to protect replication forks, nucleotide depletion, ionizing radiation,
oxidative stress, oncogenic signaling, DNA-damaging drugs, uncoordinated replicationtranscription conflicts, chromosomal missegregation, and endogenous retro-elements
activation. If replication stress is not resolved in a timely manner, stalled replication
forks are susceptible to fork collapse, leading to double-strand breaks (DSBs) and
genomic instability [3]. Chromosomal rearrangements might be accompanied with
breaks in the DNA or ssDNA gaps or stretches generated by stalling and/or collapse of
replication forks. This might be caused primarily by secondary DNA structures or by
failure in the replication machinery, or the double-stranded-break repair machinery [2].
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1.2

Genomic instability and innate immune response
Deficiency in several key players in DNA repair and DNA damage response have

been linked to innate immune response [4-9]. It has been shown that RAD51 deficiency
triggers an innate immune response that leads to increased immune cell infiltration and
better response to radiation combined with immune checkpoint blockade therapy [10].
BRCA2 deficient cells have shown a similar response in triggering an innate immune
response with PARP inhibitor treatment where the deficient cells will have increased
cytokines gene expression pattern after PARP inhibitor treatment [11]. A syndrome
associated with impaired DDR (Ataxia telangiectasia (A-T)) due to ATM gene mutations
exhibits pronounced immunodeficiency symptoms [12-14]. Several studies have shown
that DNA damage results in accumulation of micronuclei or cytoplasmic DNA that can
be recognized by cGAS activating cGAS/STING pathway and induction of the innate
immune signaling [4, 15-17]. Additionally, genetic disorders that affect DNA damage
response also trigger cytokines secretion and lead to auto-immune and inflammatory
diseases (REF). DNA repair errors in tumors may also lead to an increase of cytosolic
DNA triggering cGAS-STING-dependent response [7]. The innate immune system
provides a fast-early response against pathogens which depend on the recognition of
pathogen-associated molecular patterns (PAMPs) to form local immune responses and
danger-associated molecular patterns (DAMPs) after injury or during sterile
inflammation. PAMPs and DAMPs are sensed by pattern recognition receptors (PRRs)
[18, 19], including Nod-like receptors (NLRs) [20], Toll-like receptors (TLRs) [21],
retinoic acid–inducible gene I (RIG-I)–like RNA receptors[22], and cytosolic DNA
receptors [9, 23]. The cyclic guanosine 5′-monophosphate–adenosine 5′monophosphate (cGAMP) synthase (cGAS) is among the PRRs that sense cytosolic
2

DNA. cGAS plays a key role in detecting cytosolic DNA (figure 1 [24]). cGAS recognize
either cytosolic DNA (circular DNA, supercoiled DNA, double stranded DNA and single
stranded DNA that can form secondary structure) or micronuclei and bind to the
enclosed DNA causing the micronuclear envelop to rupture [4, 12-14, 25-30]. Upon
binding to DNA, cGAS catalyzes cGAMP formation from adenosine 5′-triphosphate
(ATP) and guanosine 5′-triphosphate (GTP). The cGAMP binds to the adaptor,
stimulator of interferon genes (STING), which induces the phosphorylation of IKK that
activates nuclear factor κB (NF-κB) and (TANK)–binding kinase 1 (TBK1). The activity
of TBK1 is regulated by the phosphorylation of a serine residue (Ser172). The
phosphorylated TBK1 then phosphorylate and activate interferon regulatory factor 3
(IRF3). The phosphorylated IRF3 dimerizes and translocates into the nucleus to induce
the production of type I interferon [27, 29, 31-33]. Thus, the cGAS/STING pathway
provide the link between innate immune response and genome instability. Additionally,
it paves the road for new or modified cancer therapies.

3

Figure 1: Activation of the cGAS-STING pathway in the innate immune response
to cytosolic DNA from exogenous and endogenous sources. shows different ways
to activate cGAS and how the signal is transduced.
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1.3

Consequences of cGAS activation
cGAS has been described to play a complex and paradoxical role in response to

genomic instability. On the one hand, cGAS activation can lead to STAT1 response
that results in increased immune cell infiltration, secretion of proinflammatory cytokines
and induction of apoptosis, on the other hand, it can lead to STAT3 axis which promote
metastasis, tumor growth and proliferation [34]. Activation of STAT1 is achieved by a
phosphorylation on the Y701 residue, which occurs in response to different interferons
and cytokines, followed by STAT1 dimerization an, translocation to the nucleus, acting
as a transcription factor [35-37]. cGAS activation can have contrasting roles in tumor
development. The cGAS-dependent innate immune response can lead to immune cells
recruitment to the tumor environment for tumor suppression. On the other hand, the
cGAS-STING pathway has been described to be the main regulator in promoting
metastasis and therapeutic resistance if senescence associated secretory phenotype is
induced [34, 38]. Dysregulation of this process may affect tumor sensitivity to irradiation
and immune checkpoint blockade treatment. However, the consequence of replication
stress on the induction of innate immune response is not known.

5

1.4

DNA replication stress
DNA replication stress occurs when a sufficient number of DNA replication forks

stall due to various endogenous and exogenous stresses including DNA damage,
excessive compacting of chromatin (preventing replisome access), over-expression of
oncogenes, depletion of nucleotides, uncoordinated replication–transcription conflicts,
or difficult-to-replicate genome structures [25, 28, 39-41]. DNA damage response
involves multiple cellular processes such as cell cycle checkpoint and DNA repair.
Unquestionably, ssDNA is generated by resection at the double strand breaks, that can
then activate the ssDNA-signaling pathways where the ssDNA will be protected from
excessive degradation and then repaired with the appropriate repair pathway.
Replication fork blockage and stalling are examples of replicative stress events that
leads to the accumulation of ssDNA gaps [1, 42-44]. The stability of the stalled
replication fork integrity is decreased as an early consequence for replication stress.
Stalled replication forks are vulnerable to degradation by nucleases that have the ability
to process stalled replication intermediates upon replication stress [42]. Hydroxyurea
(HU) is an antineoplastic agent that inhibit ribonucleoside diphosphate reductase
enzyme, an enzyme that reduces intracellular nucleotide pools and acts as S-phasespecific agent inhibiting synthesis of DNA and ultimately cellular cytotoxicity [45-48].
Different cellular mechanisms have evolved to provide end fork protection and sustain
the stability of replication forks integrity (REF). Protection of the integrity of the stalled
replication forks is critical for cells to respond to replication stress, and to minimize the
impact of this stress on the stability of the genome, which can contribute to tumor
formation. Previously, RAD51, BRCA1, BRCA2, FANCD2 and Abro1 were shown to
play a role in stabilizing and protecting stalled replication fork. In the absence of fork
6

stabilizing factors, DNA2 or MRE11 nucleases degrade nascent DNA strands at the
stalled replication forks (figure 2 [49]) [49-51]. Replication stress is closely related to
DNA double strand breaks. Indeed, the prolonged arrest of replication forks creates
DSBs, and, mutually, if a replication fork reaching a gap or a nick in the parental DNA is
converted to a DSB [2, 41, 52-54]. Additionally, homologous recombination factors
such as RAD51 and BRCA2 act to protect the stalled replication fork from nucleasemediated degradation, and restarts replication. High levels of replication stress and
compromised DNA repair are characteristic of many cancers [55]. Consequently,
targeted cancer therapies could be developed that capitalize on increased replication
stress to selectively kill cancer cells with defects in the replication stress response [56].
Therefore, research into the cellular response to replicative challenges is necessary to
both understand tumorigenesis and to identify potential targets for cancer treatment.

7

Figure 2: Protection of stalled fork stability after fork reversal. From Xu, S. et
al. Abro1 maintains genome stability and limits replication stress by protecting
replication fork stability. Genes Dev 31, 1469-1482, (2017).
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1.5

Abro1
Abro1 is a paralog of a BRCA1-interacting protein Abraxas, and is a scaffold

protein that forms a complex named BRISC complex. BRISC complex is
deubiquitination complex that specifically cleave K63-Ubiquitin chains [57-61]. Abro1
has been shown to play a crucial role in the induction of an innate immune response
following stimulation with LPS by regulating NLRP3 inflammasome activation and
IFNAR1 receptor ubiquitination [62, 63]. Abro1 also plays a role in regulating the
hematopoietic stem cell expansion by regulating the levels of K63-ubiquitination of
Janus kinase 2 (JAK2) [64]. Furthermore, Abro1 is an important player in the protection
of stalled replication fork integrity. As it protects the stalled replication forks through
inhibiting DNA2 nuclease/WRN helicase-dependent degradation of reversed stalled
forks. Abro1 deficient cells showed increased accumulation of micronuclei, nuclear
abnormalities, degradation of newly synthesized DNA and accumulation of ssDNA at
the stalled forks which are dependent on DNA2 nuclease activity and WRN helicase.
All the aforementioned phenotypes indicate that Abro1 deficient cells have high levels
of genomic instability. Abro1 deficient mice showed increased levels of IL6 and TNFalpha in blood, increased number of B cells and T cells, enlarged spleen
(splenomegaly) and increased immune cell infiltration in major organs [49]. These
findings suggest that Abro1 deficiency in DNA replication stress response and
maintenance of genomic stability might be linked to inflammation and immune
response.

9

1.6

Objective
Better understanding of the link between replication stress caused by fork

protection defect and innate immune response is necessary to understand how
replication stress affects the neighboring cells and the extracellular environment, and
how such an effect is important for immune cell migration and infiltration. Here, I found
that Abro1 deficiency triggers an innate immune response due to the failure to protect
stalled replication fork integrity which is sensed by cGAS-STING and leads to
chemokine secretion and immune cell migration.
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Chapter 2: Abro1 limits cGAS-STING-dependent innate immune response in
response to replication stress

2.1

Introduction:
Several recent research articles indicate that genomic instability and DNA

damage or stress will trigger innate immune activity especially through activating the
cGAS/STING pathway through accumulating cytoplasmic DNA or micronuclei [4, 15, 16,
25, 26, 28, 30, 34, 38]. Protection of stalled replication forks is a key step in the response
to replication stress for maintaining genome stability. However, much remains unknown
about whether or not the failure to protect the stalled replication fork triggers activation
of innate immune response or how this mechanism works. Previous studies in our lab
have established that Abro1 plays a role in protecting the integrity of stalled replication
forks during replication stress through inhibiting the activity of DNA2 nuclease and WRN
helicase. In addition, Abro1 null mice showed several signs of increased inflammation
and innate immune activity such as elevated levels of IL6 and TNF-alpha in the blood,
splenomegaly and increased immune cell infiltration in major organs [49]. However, it is
not clear whether this is connected to the role of Abro1 in protecting stalled replication
fork stability.
In this chapter, I aim to find the connection between the failure to protect the
stalled replication fork integrity in Abro1 deficient cells with induction of an innate
immune response and try to find the innate sensor for such a response.

11

2.2

Results:

2.2.1 Abro1-deficiency leads to elevated STAT1 and TBK1 phosphorylation upon
replication stress
To test whether Abro1 deficiency triggers an innate immune response, I tested
the cell-intrinsic response after replication stress in U2OS (human osteosarcoma cell
line) cells. I used two innate immune markers: STAT1 phosphorylation and TBK1
phosphorylation. Activation of STAT1 is achieved by phosphorylation on Y701, which
occurs in response to different interferons and cytokines. The activity of TBK1 is
regulated by the phosphorylation of a serine residue (Ser172). TBK1 phosphorylation
occurs when STING is activated. Upon HU treatment, at different time points, I found
that Abro1 KO U2OS cells showed elevated levels of STAT1 phosphorylation and
TBK1 phosphorylation (figure 3A), suggesting that loss of Abro1 leads to induction of
the innate immune response. Importantly, the elevated STAT1 phosphorylation level
was restored when GFP-tagged WT Abro1 was expressed in the Abro1 KO U2OS cells
(figure 3B). This data indicates that Abro1 deficiency in U2OS cells leads to activation
of the innate immune response marked by elevated levels of pTBK1 and pSTAT1.
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Figure 3: Loss of Abro1 in U2OS cells leads to increased STAT1 and TBK1
phosphorylation in respones to replication stress.
A. Abro1-deficiency leads to elevated pSTAT1 in cells treated with HU. WT or Abro1
KO U2OS cells were treated with HU (4 mM). B. Expression of GFP-tagged full-length
Abro1 in Abro1 KO cells reduced the elevated pSTAT1 levels in response to HU.
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To confirm the results obtained from U2OS cells, I also examined Abro1deficient mouse embryonic fibroblast cells (MEFs). I found that Abro1-/- MEF also
showed elevated levels of STAT1 and TBK1 phosphorylation in response to HU (figure
4), indicating that Abro1-deficiency in MEFs also leads to activation of the innate
immune response. Thus, the activation of the innate immune response due to loss of
Abro1 does not only occur in tumor cells (e.g. U2OS), but also in normal fibroblast cells
(e.g. MEFs). Thus, it is likely that Abro1-deficiency in cells results in activation of the
innate immune signal in response to replication stress regardless of cell type.
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Figure 4: Abro1-/- MEFs showed increased STAT1 and TBK1 phosphorylation in
response to HU . Abro1+/+ or -/- MEFs were treated with HU (4 mM). western blots
were carried out with lysate froms cells treated with HU at indicated time.
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Camptothecan (CPT) inhibits the activity of the enzyme DNA topoisomerase-I
(topo-I) and low dose CPT (25 nM) has been shown to induce replication fork stalling
and reversed fork formation [65]. I examined the effect of low dose CPT on the
induction of the innate immune response in Abro1 KO cells. I found treatment of lowdose CPT also led to elevated levels of STAT1 phosphorylation (figure 5A), indicative
of activation of the innate immune response. Additionally, Abro1-/- MEF cells showed a
similar phenotype when treated with low-dose CPT (figure 5B). Therefore, the innate
immune response is not specific to HU treatment, as it was observed with other agents
causing replication stress.

16

Figure 5: Abro1 –deficient cells showed increased STAT1 and TBK1
phosphorylation after CPT treatment.
A. Elevated pSTAT1 in Abro1 KO U2OS cells treated with CPT (25 nM). B. Elevated
pSTAT1 and pTBK1 in Abro1 -/- MEFs treated with CPT (25 nM).
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2.2.2 IL6 and CXCL10 are upregulated in Abro1 deficient cells after replication
stress
Interleukin 6 (IL-6) is an interleukin that acts as a pro-inflammatory cytokine. IL6
is often secreted by cells responding to PAMPs or DAMPs upon recognition with PRRs.
IL6 secretion will lead to activation of the JAK/STAT pathway and induction of an innate
immune response. C-X-C motif chemokine ligand 10 (CXCL10) is a small cytokine
belonging to the CXC chemokine family. STAT1 acts as a transcription factor for
CXCL10. CXCL10 secretion functions as a chemoattractant for
monocytes/macrophages, T cells, NK cells, and dendritic cells, promotes T cell
adhesion to endothelial cells, antitumor activity, and inhibits bone marrow colony
formation and angiogenesis [66, 67]. Several studies used IL6 and CXCL10 gene
expression profile as markers for innate immune activity, cGAS/STING activation and
inflammation [4, 15, 17, 68, 69]. Thus, I examined IL6 and CXCL10 gene expression
pattern as other outputs for innate immune response in both Abro1 KO U2OS cells and
Abro1-/- MEFs. Consistent with STAT1 phosphorylation and TBK1 phosphorylation
results, I found that Abro1 deficiency and subsequent HU treatment led to upregulation
of IL6 and CXCL10 gene expression pattern normalized to endogenous control in
U2OS (figure 6A) and in MEFs (figure 6B). Collectively, these results indicate that
Abro1 limits replication stress-induced innate immune response.
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Figure 6: IL6 and CXCL10 are upregulated in Abro1 deficient cells after
replication stress
A. Upregulation of IL6 and CXCL10 expression in Abro1 KO U2OS treated with HU.
Levels of IL6 and CXCL10 mRNAs were detected by real-time qPCR in triplicates and
relative fold change was quantified. One-way Anova was used for statistics. B.
Upregulation of IL6 and CXCL10 expression in Abro1-/- MEFs treated with HU. Levels
of IL6 and CXCL10 mRNAs were detected by real-time qPCR and relative fold change
was quantified. One-way Anova was used for statistics.
19

2.2.3 Abro1 deficiency triggers the innate immune response in a cGAS/STINGdependent manner
Several recent research articles indicate that genomic instability and DNA
damage can trigger innate immune response through activating the cGAS/STING
pathway by cGAS detecting cytoplasmic DNA or micronuclei [4, 15, 16, 25, 26, 28, 30,
34, 38]. Since we detected increased innate immune signaling in Abro1 deficient cells
after replication stress, I examined if the induced innate immune response is cGAS
dependent. I preformed cGAS knockdown and found a decrease in STAT1
phosphorylation and TBK1 phosphorylation levels in Abro1 KO U2OS cells upon cGAS
depletion (figure 7A). Additionally, cGAS KD reduced IL6 and CXCL10 gene expression
levels (figure 7B). Consistent with the results detected in U2OS cells, examination of
Abro1-/- MEFs showed a decrease in STAT1 phosphorylation levels after cGAS KD
(figure 7C). Collectively, these data show that upon depletion of cGAS, elevated innate
immune response due to Abro1-deficiency in response to replication stress is
diminished.

20

Figure 7: Abro1 deficiency triggers the innate immune response in a cGASdependent manner.
A. cGAS KD decreases the elevated pSTAT levels in Abro1 KO U2OS cells upon
treatment of HU. B. cGAS KD decreases the levels of IL6 and CXCL10 mRNA in Abro1
KO U2OS cells upon HU treatment. Levels of IL6 and CXCL10 mRNAs were detected
by real-time qPCR in triplicates and relative fold change was quantified. Two-way
Anova was used for statistics. C. cGAS knockdown decreases the elevated pSTAT
levels in Abro1 -/- MEF cells upon treatment of HU.

21

To further confirm that the cGAS/STING pathway is activated in Abro1 deficient
cells, I tested whether the elevated innate immune response caused by Abro1deficiency in response to replication stress requires the presence of STING. I
preformed STING knockdown and tested for phosphorylation of STAT1 and TBK1 in
Abro1 KO U2OS cells (figure 8). As expected, STING KD cells showed decreased
levels of phosphorylated TBK1 and phosphorylated STAT1. Thus, the innate immune
response triggered by Abro1 deficiency upon replication stress is STING dependent.
Together, these results indicate that Abro1 deficiency triggers cGAS/STINGdependent innate immune response in response to replication stress.
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Figure 8: Abro1 deficiency triggers the innate immune response in a STINGdependent manner.
STING knockdown decreases the elevated pSTAT1 and pTBK1 levels in Abro1 KO
U2OS cells upon treatment of HU (4mM).
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2.3 Summary:
Abro1 plays an important role in protecting the stalled replication fork integrity
during replication stress. Failure to protect the integrity of the fork due to Abro1
deficiency leads to fork degradation and accumulation of ssDNA at the replication fork
[49]. In this chapter, my studies showed that there is an induction of innate immune
response in Abro1 deficient cells in response to replication stress marked by increased
STAT1 phosphorylation, increased TBK1 phosphorylation, and elevated IL6 and
CXCL10 gene expression. I also showed that the induced innate immune response in
Abro1-deficient cells is cGAS and STING dependent as knockdown of cGAS or STING
decreased the STAT1 phosphorylation, TBK1 phosphorylation, IL6 gene expression
and CXCL10 gene expression in Abro1-deficient U2OS cells and MEFs. Thus, failure to
protect the stalled replication fork integrity leads to activation of the cGAS/STING
pathway triggering an innate immune response.
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Chapter 3: Abro1 deficiency leads to accumulation of cytoplasmic DNA in
response to replication stress
3.1

Introduction:
The presence of cytoplasmic DNA or micronuclei accumulation activates

cGAS/STING pathway [4, 6, 7, 9, 25, 27, 29, 33, 34, 52]. Our lab has previously
established that Abro1 plays a role in the protection of the stalled replication fork
preventing fork degradation; loss of Abro1 leads to increased resection of the stalled
fork and ssDNA accumulation in the nucleus. My data showing that Abro1-deficiency
leads to cGAS-STING-dependent activation of the innate immune response, suggests
a link between stalled fork degradation and activation of the innate immune response
[49]. It is possible that stalled fork degradation due to loss of Abro1 leads cytoplasmic
DNA that triggers the cGAS-STING-dependent activation of the innate immune
response. In this chapter, I aim to determine whether Abro1-deficiency leads to
accumulation of DNA in the cytoplasm.
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3.2

Results:

3.2.1 Increased cytosolic DNA in Abro1-deficient cells in response to replication
stress.
I examined the cytoplasmic DNA levels in Abro1-deficient cells upon replication
stress. When I used pico-green which stains double-stranded DNA or single-stranded
DNA that forms a secondary structure to stain cells, I found that Abro1 KO cells
showed a great amount of cytoplasmic pico-green staining when compared to the
control (figure 9A). It indicates that Abro1 KO cells exhibited increased cytoplasmic
DNA accumulation. The staining intensity was further enhanced upon HU treatment at
different times. These results indicate that loss of Abro1 leads to accumulation of
cytoplasmic DNA in the cells in response to replication stress.
Additionally, as a confirmatory method, I carried out cell fractionation followed by
extraction of DNA from the cytoplasmic fraction (figure 9B). By quantifying DNA
extracted from the cytoplasm fraction, I found that Abro1 KO cells contained much
more cytoplasmic DNA than the WT control and HU treatment further increased the
amount (figure 9C). Therefore, Abro1-deficiency leads to accumulation of cytoplasmic
DNA in cells.
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Figure 9: Abro1 deficient cells accumulate cytoplasmic DNA.
A. Increased cytosolic DNA detected by Pico green in cells treated with 4 mM HU. B. A
schematic shows the experiment for isolation of cytosolic DNA. C. Increased
cytoplasmic DNA levels quantified by Nanodrop.
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3.2.2 Abro1 limits cytosolic ssDNA accumulation in response to replication
stress.
In Abro1-deficient cells, stalled fork degradation is dependent on DNA2
nuclease. Increased resection leads to generation of ssDNA at the stalled fork. We
hypothesize that ssDNA generated due to fork degradation may be released into the
cytoplasm leading to ssDNA accumulation in the cytoplasm. To test this, I used
immunofluorescence staining using ssDNA antibody for detection of ssDNA in the
cytoplasm. I found increased staining in the cytoplasm of Abro1 KO U2OS cells which
was further increased with HU treatment. The amount of ssDNA was quantified by the
fluorescence intensity of the ssDNA antibody staining (figure 10A).
In addition, I carried out cell fractionation and isolation of DNA from the
cytoplasmic fraction, followed by quantification of the amount of cytoplasmic ssDNA
using the Qubit ssDNA kit. I found that Abro1 deficient cells accumulated much more
ssDNA in the cytoplasm when compared to the control (figure 10B).
Together, these results indicate that Abro1-deficiency leads to cytoplasmic ssDNA
accumulation in response to HU.
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Figure 10: Abro1 limits cytosolic ssDNA accumulation in response to replication
stress.
A. Increased cytosolic ssDNA in Abro1 KO cells in response to HU. Fluorescence
intensity of cytoplasmic ssDNA was quantified. Cytosolic ssDNA quantification of mean
fluorescence intensity (MFI) per cell was shown with mean ± SD, n is between 170-184
for each sample. One-way Anova was used for statistics. One-way Anova was used for
statistics. B. Increased cytoplasmic ssDNA levels was quantified by Qubit ssDNA kit.
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3.3

Summary
Based on the results in Chapter 2, I aimed to understand how the cGAS/STING-

dependent innate immune response is triggered in Abro1-deficient cells in this chapter.
Since cGAS can be activated by cytoplasmic DNA, I tested whether Abro1-deficient
cells accumulates cytoplasmic DNA. I found that Abro1 deficiency triggers cytoplasmic
accumulation of DNA in response to replication stress. Additionally, ssDNA antibody
staining revealed that ssDNA is accumulated in the cytoplasm in Abro1-deficient cells,
suggesting that cytoplasmic ssDNA due to loss of Abro1 might play a role in cGAS
activation and induction of the innate immune response.
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Chapter 4: Abro1 deficiency-induced activation of the innate immune response is
linked to degradation of stalled replication forks
Introduction:
My work has shown that Abro1-deficiency leads to accumulation of ssDNA in the
cytoplasm and induction of the cGAS-STING-dependent innate immune signaling in
response to replication stress. It is not known whether these are connected to the
deficiency of Abro1 in protecting stalled replication forks. In this chapter, I aim to
determine whether the accumulated ssDNA in the cytoplasm is dependent on stalled
replication fork degradation in Abro1-deficient cells. I also aim to determine whether the
degradation of the stalled replication fork is linked to the induction of innate immune
response in Abro1 deficient cells.
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Results
4.2.1 DNA2 knockdown eliminates cytosolic ssDNA
It has been established by our lab that Abro1 protects the stalled replication fork
by inhibiting DNA2 nuclease activity and inhibition of DNA2 restores fork stability in
Abro1 deficient cells [49]. We hypothesized that restoring stalled fork integrity in Abro1deficient cells decreases generation of ssDNA and eliminates cytosolic ssDNA
accumulation. I thus examined the ssDNA levels in the cytoplasm in Abro1 deficient
cells depleted of DNA2. I knocked down DNA2 using siRNAs and carried out
immunostaining of ssDNA using ssDNA antibodies in Abro1 KO or control WT cells
untreated or treated with HU (figure 11A). Quantification of cytoplasmic ssDNA
fluorescence (figure 11B) showed that whereas HU induced a robust increase of
ssDNA accumulated in the cytoplasm in Abro1 KO cells, knocking down DNA2 greatly
decreased the amount of ssDNA in the cytoplasm. These results indicate that cytosolic
ssDNA accumulation in Abro1-deficient cells is linked to the degradation of the stalled
fork and restoring fork stability by DNA2 knockdown reduces the amount of cytosolic
ssDNA.
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Figure 11: DNA2 knockdown eliminates cytosolic ssDNA
A. Knockdown of DNA2 decreases cytosolic ssDNA in Abro1 KO U2OS cells. Cells
were untreated or treated with HU (4 mM). Immunofluorescence was carried out with
ssDNA antibody. B. Fluorescence intensity of cytoplasmic ssDNA were quantified.
Mean fluorescence intensity (MFI) per cell was quantified and shown with mean ± SD,
n is between 170-182 for each sample. One-way Anova was used for statistics.
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4.2.2 DNA2 knockdown reduces activation of the innate immune response in
Abro1-deficient cells
Since my results showed that that ssDNA accumulation in the cytoplasm in
Abro1 deficient cells is dependent on DNA2, I tested whether the induction of innate
immune response in Abro1 deficient cells is also dependent on DNA2. I preformed
DNA2 knockdown and found that DNA2 knockdown reduced the increased
phosphorylation of STAT1 in Abro1 KO U2OS cells (figure 12A). Additionally, the
upregulation of CXCL10 and IL6 gene expression pattern was also restored when
DNA2 is depleted (figure 12B).
Consistent with these results, I found that DNA2 KD in Abro1-/- MEF cells also
decreased the levels of STAT1 phosphorylation (figure 12C) and the upregulation of
CXCL10 and IL6 gene expression (figure 12D). Thus, the innate immune response in
Abro1-deficient cells is dependent on DNA2. Together, these results indicate that
protection of the stalled replication fork integrity from DNA2 degradation plays an
important role in inhibiting innate immune response.
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Figure 12: DNA2 knockdown reduces activation of the innate immune response
A. DNA2 KD decreases pSTAT1 in U2OS. B. DNA2 KD reduce IL6 and CXCL10 in
U2OS using qPCR in triplicates and two-way Anova was used. C. DNA2 KD
decreases pSTAT1 in MEFs. D. DNA2 KD reduces IL6 and CXCL10 in MEFs using
qPCR in triplicates and two-way Anova was used
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4.2.3 Inhibition of MRE11 activity does not have an effect on cytosolic ssDNA
and the innate immune response of Abro1-deficient cells
As It was previously found that inhibiting MRE11 with an inhibitor, Mirin, does
not restore replication fork integrity in Abro1 deficient cells [49], I tested whether
treatment of mirin has an effect on the accumulation of the cytoplasmic ssDNA or the
induction of innate immune response in Abro1-deficient cells. I found that mirin did not
have much effect on the cytoplasmic ssDNA levels in Abro1 deficient cells (figure 13AB). In addition, treating Abro1-deficient cells with Mirin did not affect the levels of
STAT1 phosphorylation (figure 13C). Thus, treatment of mirin which does not restore
fork integrity in Abro1-decient cell fails to limit the induction of the innate immune
response in Abro1-deficients.
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Figure 13: Inhibition of MRE11 activity does not have an effect on cytosolic
ssDNA and the innate immune response of Abro1-deficient cells
A. Inhibition of Mre11 does not decrease cytosolic ssDNA in Abro1 KO U2OS cells. B.
Fluorescence intensity of cytoplasmic ssDNA were quantified. Quantification of
cytosolic ssDNA (mean fluorescence intensity, MFI) was shown with mean ± SD, n is
between 185-200 for each sample. One-way Anova was used for statistics. C. Inhibition
of Mre11 does not affect pSTAT levels in Abro1 KO U2OS cells.
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4.2.4 Restoring fork integrity by knocking down RAD51 or WRN reduces the
induction of the innate immune response in Abro1-deficient cells
Abro1 plays a role in the protection of the stalled replication fork by inhibiting
DNA2 nuclease-mediated fork degradation with the help of WRN helicase. Additionally,
it has been shown that RAD51 depletion rescued the defect in fork protection in Abro1
deficient cells [49]. To further confirm that the induction of the innate immune response
in Abro1-deficient cells is linked to the degradation of stalled replication forks, I tested
whether restoring fork integrity by depletion of WRN or RAD51 eliminates the induction
of the innate immune response in Abro1-deficient cells. I found that WRN KD reduced
the increased phosphorylation of STAT1 in Abro1 KO U2OS cells (figure 14A). In
addition, RAD51 KD reduced the increased phosphorylation of STAT1 and TBK1 in
Abro1 deficient cells. Depletion of RAD51 led to increased phosphorylation of STAT1
and TBK1 in U2OS cells since RAD51 KD caused fork protection in wild type cells in
our published work (REF). (figure 14B). Together, these results indicate that the innate
immune response triggered in Abro1 deficient cells is linked to the failure to protect the
stalled replication fork and restoring replication fork integrity abolishes the induction of
innate immune response.
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Figure 14: Restoring fork integrity by knocking down RAD51 or WRN reduces the
induction of the innate immune response in Abro1-deficient cells.
A. Knockdown of WRN decreases pSTAT1 in Abro1 KO U2OS cells upon treatment of
HU. B. Knockdown of RAD51 decreases pSTAT1 and pTBK1 levels in Abro1 KO
U2OS cells.

39

Summary
I found that cytoplasmic accumulation of ssDNA in Abro1 deficient cells is
dependent on the presence of DNA2 and not MRE11 activity. I also found that the
innate immune response induced upon replication stress in Abro1 deficient cells is also
dependent on the presence of DNA2 but and not MRE11 activity. Thus, the induction of
the innate immune response in Abro1 deficient cells is likely trigged by the
accumulation of ssDNA in the cytoplasm due to the failure to protect the stalled
replication fork in the absence of Abro1. Knocking down WRN or RAD51, which
restores the fork protection in Abro1-deficient cells, led to a decrease of STAT1
phosphorylation levels and TBK1 phosphorylation in Abro1 deficient cells. Thus, it is
likely that fork degradation due to loss of Abro1 led to cytoplasmic ssDNA accumulation
which triggers cGAS/STING-dependent innate immune response. Restoring fork
integrity abolish the cytoplasmic accumulation of ssDNA and eliminates the induction of
the innate immune response.
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Chapter 5: Abro1 deficiency-induced innate immune response in non-immune
cells promotes immune cell migration
Introduction
My work showed that Abro1-deficiency in protection of the stalled replication fork
triggers replication stress-induced cGAS-STING-dependent innate immune response.
Induction of innate immune signaling can alter the immune cell behavior through
secretion of different cytokines and chemokines that change the microenvironment and
coordinate cell-cell communication. Interestingly, previous analysis of Abro1 null mice
from our lab has shown that Abro1 null mice showed symptoms of increased
inflammation and activation of immune signaling. This was observed by elevated levels
of IL6 and TNF-alpha in blood, enlarged spleen (splenomegaly) and increased immune
cell infiltration in major organs.
In this chapter, I aim to determine the effect of Abro1-deficiency-induced
activation of innate immune signaling upon replication stress. I examined whether
Abro1-deficient cells secret proinflammatory cytokines and whether Abro1-deficiency
induces secretion of factors that promote immune cell migration.

Results
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Replication stress leads to cytokines secretion.
I investigated the downstream effect of the induced innate immune response
from Abro1 deficiency induced replication stress. I performed a cytokine array to test for
the difference in secreted cytokines from U2OS with the presence and absence of
Abro1 and in the presence and absence of HU to elevate the replication stress. After
culturing and treating Abro1 KO U2OS cells, I collected the supernatant media and
preformed a cytokine array panel. I found that 10 cytokines (MIF, CCL2, CCL3, CCL4,
IL6, IL8, IL18, CXCL12, GM-CSF and Serpin E1) were elevated in the supernatant
media in case of Abro1 deficiency (figure 15A). This indicates that the induced innate
immune response due to Abro1 deficiency leads to secretion of different amounts of
specific cytokines. To further confirm this, I examined CCL2, IL8, IL18 and GM-CSF
gene expression pattern using qPCR from U2OS cells and consistently I found that
their gene expression is upregulated in Abro1 KO U2OS cells (figure 15B). Thus,
Abro1-deficiency-induced replication stress leads to increased production and secretion
of proinflammatory cytokines and chemokines.
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Figure 15: Replication stress lead to cytokines secretion.
A. Cytokine-array analyses of secreted factors in cells untreated or treated with HU.
Media from cultured Abro1 WT or KO U2OS cells untreated or treated with HU (4 mM,
16h) were used with cytokine array and then membranes were quantified using image
J. B. Upregulation of CCL2, GM-CSF, IL8 and IL18 gene expression in Abro1 KO
U2OS treated with HU. Levels of cytokines were detected by real-time in triplicates
and relative fold change was quantified. One-way Anova was used for statistics.
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Replication stress leads to increased immune cell migration.
Analysis of different cytokines secretion in Abro1 KO U2OS cells showed that
the secreted cytokines plays a role in the chemotaxis pathway of immune cells (Table
1). The secreted chemokines work as chemoattractants for different immune cells, such
as T-cell, basophil, NK cell, dendritic cell, macrophage, eosinophil, neutrophil,
astrocyte, fibroblast and osteoclast. The increase in those secreted cytokines will most
likely lead to increase in immune cell migration. Thus, I examined the ability of the
media collected from MEF cells to undergo replication stress (whether due to Abro1
deficiency or HU treatment) to promote immune cells migration using the invitro
chemotaxis assay (figure 16A). I isolated immune cells from mice peritoneum and
tested for the effect of media from Abro1-/- MEF cells on the migration pattern of the
immune cells (figure 16B). I found that media from Abro1-/- MEF cells or after HU
treatment have an enhanced effect on the immune cell migration. And consistently, I
tested for the effect of DNA2 KD or cGAS KD (figure 16C). Unfailingly, I found that
DNA2 KD or cGAS KD rescue the increased immune cell migration after replication
stress indicating that the secretion of proinflammatory cytokines and the promotion of
immune cell migration is dependent on the cGAS/STING pathway and replication fork
protection achieved by inhibition of DNA2.
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Cytokine
GM-CSF [70]
IL6 [71]
IL18 [72, 73]

MIF [74]
Serpin E1 [75]
IL8 [76, 77]
CXCL12 [78]

CCL2 [79]
CCL3 [80]

effect
Stimulates the growth and differentiation of Myelomonocytic
lineage cells particularly dendritic cells
T-cell and B-cell growth and differentiation
Induces IFNy production and promote Th1 cell activation and
upregulate FasL to enhance the cytotoxic activity of CD8+ T
cells and natural killer (NK) cells
Inhibits Macrophage migration and stimulates Macrophage
activation
Regulator of cell migration
Chemotactic of neutrophil, basophil, CD8+ subset cells
Chemotactic of neutrophil, CD34+ bone marrow cells,
thymocytes, macrophages, activated T-cell, B-cell, plasma
cell, neutrophil, dendritic cell
Chemotactic of T-cell, basophil, NK cell, immature dendritic
cell
Chemotactic of T-cell, basophil, NK cell, immature dendritic
cell, macrophage, eosinophil, neutrophil, astrocyte, fibroblast,
osteoclast

Table 1: differentially secreted immune markers from Abro1 KO U2OS cells and
their effect
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Figure 16: Replication stress leads to inceased immune cell migration.
A. A schematic of chemotaxis assay to measure immune cell migration attracted by
secreted factors from MEFs B. Replication stress induced by Abro1-/- or HU promotes
immune cell migration. Experiment were done in triplicate and analyzed by one-way
ANOVA C. Abro1-deficiency promotes immune cell migration and knockdown of cGAS
or DNA2 abolished the migration of immune cells attracted by media from Abro1-/MEFs. Experiment were done in triplicate and analyzed by two-way ANOVA
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Summary:
In previous chapters, we found that Abro1 deficiency triggers an innate immune
response. The stalled replication forks are degraded resulting in accumulation in the
cytoplasm and activation of the cGAS/STING pathway takes place. Also, triggering an
innate immune response is dependent on the fork protection defect that is found in
Abro1 deficient cells. As a consequence of replication stress and induction of an innate
immune response, I found that there is an increase in cytokines and chemokines
secretion as a cellular response changing the microenvironment. Those secreted
chemokines might work as chemoattractants for different immune cells. Additionally, I
found that replication stress will promote immune cell migration and inhibit the innate
sensor (cGAS) or achieve fork stability (Knockdown of DNA2) eliminates the increase
in immune cell migration. Therefore, Abro1 deficient cells will fail to protect the stalled
replication fork from degradation by DNA2 nuclease. Then the degraded forks will
accumulate in the cytoplasm in a single stranded DNA form that activates cGAS and
triggers an innate immune response. As a consequence, cells will secrete cytokines
and chemokines that modify the microenvironment and promote immune cell migration.
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Chapter 6: Discussion and Future Directions

Figure 17: The proposed model for the role of Abro1 in induction of immune
response.
In the absence of Abro1 and following exposure to replication stress, stalled replication
forks are degraded by hyperactive DNA2. ssDNA from degraded forks are accumulated
in the cytoplasm and activate cGAS/STING pathway. Activation of cGAS/STING
pathway increase cytokines secretion which in turn direct immune cells towards the site
of replication stress. Created with BioRender.com.
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6.1

Abro1 is important for preventing replication stress induced innate
response by cGAS/STING pathway.
The stability of the genome must be maintained at all times to ensure accurate

transmission of genetic information. DNA is constantly exposed to various stresses,
endogenous and exogenous, that cause damage and replication stress. Thus, several
pathways have evolved to ensure the complete and accurate repair of DNA [3, 81].
During DNA replication, the replication machinery must overcome several difficulties,
including consequences of oxidative stress, non-B form DNA structures (such as R
loops), tightly bound DNA-protein complexes and lesions that interfere with fork
progression which can lead to replication stress by replication fork stalling, collapse or
breakage. Several mechanisms such as oncogene activation, nucleotide pool
imbalance, repetitive sequences that are difficult to replicate, and uncoordinated
replication/transcription conflict can cause replication stress [1, 40-42, 82]. High levels
of replication stress, and DNA damage are often observed in precancerous cells or
early cancer stages, and replication stress plays a role in the development of different
tumors [55, 83-86]. Cells have evolved several pathways to protect replication forks
during replication stress. One recently discovered pathway is the role of Abro1 in
protecting the fork integrity by regulating DNA2 nuclease activity, where in absence of
Abro1, DNA2 degrades the stalled fork. It was observed that Abro1-deficient cells have
higher levels of genomic instability, seen in increased nuclear and chromosomal
abnormalities [49]. Additionally, it has been shown that increased

genomic instability

can trigger an inflammatory innate immune response through the cGAS/STING
pathway by the accumulation of micronuclei or cytoplasmic DNA [9, 16, 22, 24, 27, 29,
30, 34, 38]. The inflammatory response to damage and pathogens is a universal cell49

intrinsic response [87]. Furthermore, Abro1-null mice showed signs of increased
inflammation such as splenomegaly, increased numbers of B and T cells, elevated IL6
and TNF-alpha in the blood and increased immune cell infiltration in major organs.
Accordingly, Abro1 might play a role in the inflammatory innate immune response. I
found that the absence of Abro1 in cancer cells or in fibroblasts triggers an innate
immune response, seen in increased cytokine gene expression and increased
phosphorylation of STAT1 and TBK1. For the induction of the innate immune response,
an innate sensor is required to sense the type of danger (damage or infection) and
transduce the signal accordingly [19, 20, 24, 27, 34]. I found that in case of Abro1
deficiency, the induced innate immune signal requires cGAS as the innate sensor. This
is shown as the absence of cGAS or STING (downstream molecule of the
cGAS/STING pathway) which abolishes the increased activity of different innate
immune markers.

6.2

Cytoplasmic ssDNA accumulation in Abro1 deficient cells lead to cGAS
activity
cGAS activation requires binding to DNA either free in the cytoplasm or in the

micronuclei. This DNA could be supercoiled DNA, circular DNA, linear DNA, double
stranded DNA, or single stranded DNA that can form a secondary structure [26, 27, 29,
30]. I found that Abro1 deficient cells have increased cytoplasmic DNA, specifically
ssDNA. This accumulation is dependent on the presence of DNA2 nuclease, thus it is
coming from the failure to protect the replication fork integrity. Additionally, the inhibition
of MRE11, which does not rescue fork protection defects in Abro1 deficient cells, did
not affect ssDNA cytoplasmic accumulation. Then, I examined whether this cytoplasmic
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accumulation of ssDNA can be sensed by cGAS and trigger the innate immune signal
that I observed. I found that knockdown of DNA2 rescues the increased
phosphorylation of STAT1 and TBK1 and diminishes the upregulation of IL6 and
CXCL10 gene expression. To further confirm that DNA2 requires WRN helicase in
order to perform resection, I found that WRN KD alone is able to rescue the increased
phosphorylation of STAT1 and TBK1. Additionally, I found that inhibiting MRE11 did not
affect the levels of STAT1 phosphorylation. RAD51 is another unique protein in that its
deficiency in wild type cells leads to fork protection defects and the induction of an
innate immune response, while RAD51 deficiency in Abro1 KO cells rescues the fork
protection defect [10, 49]. Consistently, I found that RAD51 KD in Abro1 KO cells
rescues the increased phosphorylation of STAT1 and TBK1 while inducing the
phosphorylation of STAT1 and TBK1 in wild type cells. These results collectively
indicate that cytoplasmic ssDNA accumulation in Abro1 KO cells can drive cGAS
activity. Thus, failure to protect the stalled replication fork integrity will lead to
cytoplasmic ssDNA accumulation that can trigger an innate immune response by
activating cGAS.

6.3

Replication stress-induced innate immune response modifies the immune
system
Genomic stability is maintained through the precise synchronization of different

mechanisms to ensure accurate transmission of genetic material. These mechanisms
include DNA replication, repair and recombination; protection of the stalled replication
fork; cell cycle checkpoints; and chromosome segregation. All these mechanisms
prevent the proliferation of cells with DNA damage and/or genetic rearrangements.
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Ultimately, these autonomous cell responses induce senescence or cell death if the
damage cannot be fixed. Defects in the protection of the stalled replication fork and/or
different DNA repair factors are often associated with high genetic instability,
predisposition to different kinds of cancers, and premature ageing. In addition to these
different mechanisms, other mechanisms also act at the whole organism level including
the modification of the microenvironment and innate immune activity. The inflammatory
innate immune response is a universal cell-intrinsic response to pathogens and
damage [5, 6, 52, 85, 87-95]. Given this context, I aimed to examine if the innate
immune signaling observed has a broader effect on the immune system. I found that
cells under replication stress increase the secretion of certain cytokines/chemokines
(listed in table 1). Some of secreted cytokines stimulate the proliferation, growth and
differentiation of different immune cells, especially dendritic cells, macrophages, B
cells, T cells and natural killer cells. Furthermore, some of the secreted chemokines
work as chemoattractants for different immune cells (T-cell, basophil, natural killer cell,
dendritic cell, macrophage, eosinophil, neutrophil, astrocyte, fibroblast, osteoclast),
thus increasing their migration. The next step was to examine if the media containing
those cytokines would affect immune cell mobility and migration. Using an in vitro
chemotaxis assay, I found that media from cells undergoing higher levels of replication
stress (HU treatment, Abro1 KO) have the ability to attract more immune cells and
induce immune cell migration. This finding could possibly serve as an explanation for
the increased immune cell infiltration observed in Abro1 null mice. Recently, immune
checkpoint blockade therapy has been emerging as a promising cancer
immunotherapy. This therapy activates the T cells in the tumor by either blocking
CTLA4 or PDL1. One of obstacles that impedes immune checkpoint blockade therapy
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is insufficient immune cells infiltrating the tumor. This phenomenon is known as hot
tumor vs cold tumor, where hot tumors are responsive to immune checkpoint blockade
therapy while cold tumors are resistant. Several studies have proposed the idea of
combining the DNA damage response or STING agonists with immune checkpoint
blockade therapy, thereby increasing immune cell infiltration of the tumor and activating
those immune cells (converting cold tumor to hot tumor) to achieve a better response
[6, 8, 25, 28, 29, 52, 68, 88, 89, 96-99]. My results suggest Abro1 as a new possible
therapeutic target. Targeting Abro1 will likely cause increased proliferation of immune
cells [64] and increased immune cell infiltration. Thus, targeting Abro1 could possibly
convert cold tumors into hot tumors. Then, combined with immune checkpoint blockade
therapy, we can achieve better outcomes for cancer immunotherapy. As targeting
Abro1 will increase DNA2 activity and the failure to protect the stalled replication fork
integrity specifically in regions that is hard to replicate (as rDNA). Degraded forks will
be then exported to the cytoplasm and then bind to cGAS and activate the
cGAS/STING pathway. cGAS/STING activation will induce an innate immune response
that secrete certain cytokines and chemokines. Finally, those cytokines will trigger
immune cell migration (figure 19).

53

6.4

Future Directions
My results are consistent with the published results showing Abro1 could regulate

DNA2 activity. However, the exact mechanism is not known. Several possible
mechanisms for Abro1 to regulate DNA2 activity could exist. A recent article had shown
that DNA2 localization is controlled by K63 ubiquitination, where K63 ubiquitinated
DNA2 is localized to the nucleus [100]. Additionally, Abro1 forms a complex (BRISC)
that is a deubiquitination complex that specifically cleaves K63 ubiquitination [57-60,
63, 101, 102]. Thus, Abro1 might play a role in DNA2 localization by controlling DNA2
K63 ubiquitination levels.
My results also suggested that Abro1 could be used as a therapeutic target to
enhance immune checkpoint blockade therapy. Thus, we need to evaluate the
therapeutic effect of Abro1 deficiency and replication stress on immune therapy. This
could be examined using in vivo experiments. Using immunocompetent mice (wild type
and Abro1 KO) and tumor cells (such as 4T1) could be injected into mice. We can use
both Abro1 deficient and proficient tumor cells. Then treat mice with immune
checkpoint blockade and monitor the response. Additionally, we can analyze the
immune cell infiltration and activity in the tumor. Thus, we gain more insight into what
happens. We can also use immunocompromised mice as a control. This could suggest
possibilities to modulate the host immune system response and ultimately the success
of immune checkpoint blockade therapies.
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Chapter 7: Materials and Methods

7.1

Cell lines, antibodies, chemicals
Human U2OS cell lines were purchased from ATCC. Abro1 CRISPR-Cas9 KO

U2OS cell lines were generated in our lab as described [49]. U2OS cells were cultured
in McCoy’s 5A medium with 10% fetal bovine serum (FBS). Abro1 -/- and littermate +/+
mouse embryonic fibroblast (MEF) cell lines were generated in our lab [103]. MEFs
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS. All cells
were cultured at 5% CO2 at 37oC.
The antibodies used in this study include Abro1 (1:5000) [61], γ-tubulin (1:5000)
(Sigma, T-6557), DNA2 (Proteintech, 18727-1-AP) (1:500) (Abcam, ab96488) (1:1000),
RAD51 (Abcam, ab63801) (1:1000), ssDNA (EMD Millipore, MAB3868) (1:1000), WRN
(Novus, nb100-472) (1:1000), P-Stat1 (Y701) (58D6) (Cell Signaling, 9167S) (1:1000),
Stat1 (D1K9Y) (Cell Signaling, 14994S) (1:2000), TBK1/NAK (Cell Signaling, 38066S)
(1:1000), P-TBK1 (Ser172) (Cell Signaling, 5483S) (1:1000), cGAS (D1D3G) (Cell
Signaling, 15102) (1:1000), STING (D2P2F) (Cell Signaling, 13647S) (1:1000), GAPDH
Loading Control (Invitrogen, MA5-15738) (1:5000).
1x Pico-green (Life Technologies),4 mM HU (Sigma), 100 uM Mirin (Sigma),
10ng/ml LMB (Sigma) and 25 nM camptothecan (CPT) (Sigma) are used in this study.

7.2

siRNAs and shRNA
Pools of four individual siRNAs were obtained from GE Dharmacon for human

cGAS( L-015607-02-0005), mouse cGAS (L-055608-01-0005), human STING (L024333-00-0005), human WRN (L-010378-00-0005), mouse DNA2 (M-062864-0155

0005). Other siRNAs used are: control non-targeting siRNA
5'U.G.G.U.U.U.A.C.A.U.G.U.C.G.A.C.U.A.A.U.U3'; human siDNA2 #1
5'C.A.G.U.A.U.C.U.C.C.U.C.U.A.G.C.U.A.G.U.U3'; human siDNA2 #2
5'A.U.A.G.C.C.A.G.U.A.G.U.A.U.U.C.G.A.U.U.U3'; human siRAD51 #1
5'G.A.G.C.U.U.G.A.C.A.A.A.C.T.A.C.U.U.C3'; human siRad51 #2
5'A.G.C.A.G.U.G.G.U.A.A.U.C.A.C.U.A.A.U.C.A3'
Cells were transfected with siRNAs using Lipofectamine RNAiMax (Invitrogen) for
60h before stimulation of cells with HU.

7.3

Immunoblotting and immunoprecipitation
Cells were lysed using NETN buffer (50 mM Tris-HCl at pH 8.0, 150 mM sodium

chloride, 1 mM EDTA, 0.5% nonidet P-40, 1 mM dithiothreitol [DTT], 1 mM PMSF, 5
mM NaF, 1 mM Na3VO4, 50 mM β-glyceral, protease inhibitor cocktails) and
centrifuged at 15,000 rpm for 10 min at 4°C, and the supernatants were collected as
total cell lysate. Samples were boiled in SDS sample buffer (62.5mM Tris-Cl pH 6.8,
2% (w/v) SDS, 10% Glycerol, 0.1% Bromophenol Blue, 50mM DTT) before loaded onto
the protein gel. Proteins were separated by SDS-PAGE and transferred onto
nitrocellulose membranes (Millipore) using wet transfer (Bio-Rad). Membranes were
blocked with 5% (w/v) non-fat milk in 0.1% Tween-20/TBS for 1h. Primary antibodies
were used at dilutions as instructed from the antibody datasheet. Secondary HRPcoupled antibodies were used at 1:5000. Membranes were developed using Pierce™
ECL Western Blotting Substrate or SuperSignal™ West Pico PLUS Chemiluminescent
Substrate (Thermo Scientific) and imaged on a Chemidoc (Bio-Rad).

56

7.4

Immunofluorescence
Cells grown on coverslips were fixed with freshly made 3% paraformaldehyde

solution for 20 min at room temperature followed by permeabilization with 1% Triton X100 solution for 20 min on ice, washed with PBS and then incubated with indicated
primary antibodies overnight at 4°C followed by secondary antibodies conjugated with
Alexa 488 or Alexa 555 (1:1000) for 1 h at room temperature. Coverslips were then
washed with 0.1% Tween-20/PBS and mounted using DAPI containing antifade
solution (Invitrogen). Images were captured by a Nikon 80i upright microscope.

7.5

Real-time PCR
Total RNA was extracted from cells using RNasey mini kit (Qiagen), and reverse

transcribed using iScript cDNA Synthesis Kit (Bio-Rad Laboratories) according to
manufacturer’s instructions. Real-time PCR were performed by using SYBR green
supermix (Bio-Rad), and CFX-96 real-time PCR detection system (Bio-Rad). The PCR
primers used are: Human IL6 F: 5’CAGCCCTGAGAAAGGAGACAT’3, R:
5’GGTTCAGGTTGTTTTCTGCCA’3; human CXCL10 F:
5’AGCAGAGGAACCTCCAGTCT’3, R: 5’AGGTACTCCTTGAATGCCACT’3; mouse IL6
F: 5’GCTACCAAACTGGATATAATCAGGA’3, R:
5’CCAGGTAGCTATGGTACTCCAGAA’3; mouse CXCL10 F:
5’ATGACGGGCCAGTGAGAATG’3, R: 5’ATTCCGGATTCAGACATCTCT’3; human
CCL2 F: 5’TCAAACTGAAGCTCGCACTCT’3, R: 5’GGCATTGATTGCATCTGGC’3;
human GM-CSF F: 5’AATGTTTGACCTCCAGGAGCC’3, R:
5’AGTGCTGCTTGTAGTGGCTG’3; human IL8 F: 5’AGCTCTGTGTGAAGGTGCAG’3,
R: 5’TGGGGTGGAAAGGTTTGGAG’3; human IL18 F:
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5’TGCAGTCTACACAGCTTCGG’3, R: 5’GCAGCCATCTTTATTCCTGCG’3; mouse
internal control HPRT F: 5’CTGGTGAAAAGGACCTCTCG’3, R:
5’CAAGGGCATATCCAACAACA’3; human internal control B2M F:
5’TTCTGGCCTGGAGGCTATC’3, R: 5’TCAGGAAATTTGACTTTCCATTC’3.
The cycling program used was: 95 °C for 5 min; 40 cycles of 95 °C for 15 sec
and 60 °C for 30 sec. Quantification cycle (Cq) for the mRNAs of interest were
normalized to reference mRNA and data was expressed as fold change.

7.6 Total, nuclear and cytosolic DNA extraction and quantification
For total DNA extraction, cell pellets were used. For nuclear or cytosolic DNA, cell
fraction using Mitochondria Isolation Kit for Cultured Cells (Thermo Scientific) was
carried out before DNA extraction. Total, nuclear, or cytosolic fraction of cells were then
extracted by treating with DNA extraction buffer (10 mM Tris pH 8, 100 mM EDTA pH
8, 0.5% SDS, 200 μg/ml Proteinase K, 1mg/ml RNase A) and incubated at 56°C for 1
h, followed by extraction with equal volume phenol/chloroform/isoamyl alcohol (25:24:1)
and chloroform/isoamyl alcohol (24:1) sequentially. After centrifugation, supernatant
was collected and equal volume of isopropanol and 1/10 volume of 3M sodium acetate
(pH 5.8) was added and incubated at -20°C overnight for DNA precipitation. Nanodrop
(Thermo Scientific) was used for total DNA quantification. For ssDNA quantification,
Qubit™ 4 Fluorometer (Thermo Scientific) and Qubit™ ssDNA Assay Kit (Invitrogen)
and Qubit™ dsDNA BR Assay Kit (Invitrogen) were used according to manufacturer’s
instructions.
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7.7

Cytokine array analysis
3 × 10^5 cells were cultured in six-well plates for 6 h prior to treatment. Cultured

media were collected and cleared by centrifugation at 2000 g for 10 min. The 1 ml of
supernatant was diluted with 0.5 ml of the provided buffer and applied to the Proteome
Profiler™ Human Cytokine Array Kit (R&D Systems® ARY005B). Spot intensity was
quantified with ImageJ and normalized to reference spots.

7.8

Chemotaxis assay
Isolation of immune cells from mouse peritoneum were described previously

[104]. Briefly, euthanized mice were cleaned with 70% ethanol and outer skin of the
peritoneum was cut. 5 ml of 3% FBS in ice cold PBS was injected into the peritoneum.
The peritoneum was massaged to detach any immune cells. Fluid containing cells were
collected and centrifuged at 1500 rpm for 8 minutes.
Chemotaxis assay was performed using a CytoSelect 96-well cell migration assay
(5 μm; Fluorometric Format; Cell Biolabs, San Diego, CA, USA) according to the
manufacturer’s instructions. Media from Abro1 +/+ or -/- MEFs or MEFs treated with
siRNAs to DNA2 or cGAS, untreated or treated with HU were collected and cleared
with low speed centrifugation. 150 ul of supernatant after centrifugation was transferred
into the bottom wells (feeder tray). Serum-free medium containing 1 × 10^6 peritoneum
cells (100 μL) was placed in the migration chamber, and the chemotaxis plate was
cultured at 37 °C for 20 h. After incubation, migratory cells were incubated for 20 min
with 50 μL of lysis buffer/dye solution. Fluorescence was read at 480/520 nm, and
values were expressed as relative fluorescence units (RFU).
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7.9

Statistics
All lines and error bars represent mean values and standard deviation,

respectively. P-value meanings used are ns P>0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤
0.001, **** P ≤ 0.0001. All data shown is a representive experiment for other repeats.
All Experiments were done in at least 3 biological replicates except for cytokine array
panel was done only one time and the chemotaxis was done in 2 Biological replicates.
GraphPad Prism was used to plot and analyze the data. As appropriate, the Student’s
t-test, Mann-Whitney test, one-way ANOVA, two-way ANOVA, or nonparametric
Kruskal-Wallis ANOVA were used to asses statistical significance.
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